Evidence map›Paper›PMID 33689039›Full record

ArticleArchives of virology2021

Human pegivirus 1 in Cabo Verde: prevalence and genotypic distribution among HIV-infected individuals.

Isabel Inês M de Pina-Araujo, Marco Aurélio Horta, Francisco Campello do Amaral Mello, Caroline Cordeiro Soares

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Isabel Inês M de Pina-AraujoFaculdade de Ciências e Tecnologia, Universidade de Cabo Verde, Praia, Cabo Verde.
Marco Aurélio HortaPlataforma NB3, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.
Francisco Campello do Amaral MelloLaboratório de Hepatites Virais, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil. fcamello@ioc.fiocruz.br.ORCID http://orcid.org/0000-0003-4561-4332
Caroline Cordeiro SoaresLaboratório de Virologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.
Fundação Oswaldo Cruz · BRUniversity of Cape Verde · CV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human pegivirus 1 (HPgV-1) belongs to the genus Pegivirus, family Flaviviridae, and until now has been considered a non-pathogenic agent, despite being considered a risk factor for non-Hodgkin lymphoma. However, a beneficial impact of HPgV-1 on HIV disease progression has been extensively reported. Given the high prevalence of HIV in sub-Saharan Africa and the scarcity of epidemiological data for many countries of West Africa, we conducted the first study of HPgV-1 in HIV-infected individuals from Cabo Verde. To obtain new data regarding prevalence and genetic diversity of HPgV-1 in Africa, serum samples from 102 HIV-infected Cabo Verdeans were tested for the presence of viral RNA, and the circulating genotypes were identified by sequencing of the 5' untranslated region. HPgV-1 RNA was detected in 19.6% (20/102) of the samples. In 72.2% (13/18) of the samples, the virus was identified as genotype 2 (11/13 subtype 2a and 2/13 subtype 2b), and in 27.8% (5/18), it was identified as genotype 1. The estimated substitution rate of HPgV-1 genotype 2 was 5.76 × 10

Indexed as

5' Untranslated RegionsCabo VerdeCoinfectionFlaviviridae InfectionsGB virus CGenetic VariationGenotypeHepatitis, Viral, HumanHIV InfectionsHumansPhylogenyPrevalenceRNA, ViralViremia5' Untranslated RegionsRNA, Viral

Identifiers

PMID33689039
OpenAlexW3135339476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.